Androst-5-en-3β-ol | 1476-64-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Androst-5-en-3β-ol
• 英文别名: 3β-Hydroxy-androsten-5；3β-Hydroxy-androst-5-en；(3S,10R,13S)-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 1476-64-8；5232-33-7；149654-95-5
• 化学式: C₁₉H₃₀O
• 分子量: 274.447
• InChiKey: LYFPAZBMEUSVNA-PZKNQLILSA-N

物化性质

• 熔点：
  135-136.5 °C
• 沸点：
  387.1±11.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] ANTAGONISTS OF CB1 RECEPTOR.<br/>[FR] ANTAGONISTES DU RÉCEPTEUR CB1
  申请人：INST NAT SANTE RECH MED

  公开号：WO2012160006A1

  公开（公告）日：2012-11-29

  The invention relates to an antagonist of CB1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.

  本发明涉及CB1受体拮抗剂，用于治疗以下病理状况或疾病的成员组：膀胱和胃肠道疾病；炎症性疾病；心血管疾病；肾病；青光眼；痉挛性疾病；癌症；骨质疏松；代谢性疾病；肥胖症；成瘾、依赖、滥用和复发相关疾病；精神和神经疾病；神经退行性疾病；自身免疫性肝炎和脑炎；疼痛；生殖系统疾病和皮肤炎性和纤维化疾病。
• LIGANDS FOR NEMATODE NUCLEAR RECEPTORS AND USES THEREOF
  申请人：Mangelsdorf J. David

  公开号：US20070219173A1

  公开（公告）日：2007-09-20

  Anti-nematode compounds, compositions, and methods for identifying such compounds are disclosed, where the compounds have the formula I: where Q, Q′, R 1 , R 2 , and n are defined herein.

  本文披露了抗线虫化合物、组合物以及鉴定这种化合物的方法，其中化合物的公式为I：其中Q、Q'、R1、R2和n的定义如本文所述。
• Lipid Nanoparticle Based Compositions and Methods for the Delivery of Biologically Active Molecules
  申请人：Chen Tongqian

  公开号：US20090048197A1

  公开（公告）日：2009-02-19

  The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in a subject or organism. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules, such as antibodies (e.g., monoclonal, chimeric, humanized etc.), cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, dsRNA, allozymes, aptamers, decoys and analogs thereof, and small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), and RNAi inhibitor molecules, to relevant cells and/or tissues, such as in a subject or organism. Such novel cationic lipids, microparticles, nanoparticles and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism. The compositions described herein are generally referred to as formulated molecular compositions (FMC) or lipid nanoparticles (LNP).

  本发明涉及新型阳离子脂质、转染剂、微粒、纳米粒子和短干扰核酸（siNA）分子。本发明还涉及组合物和使用方法，用于研究、诊断和治疗对基因表达和/或活性调节有反应的个体或生物的特征、疾病和状况。具体而言，本发明涉及新型阳离子脂质、微粒、纳米粒子和转染剂，可以有效地转染或传递生物活性分子，如抗体（例如单克隆、嵌合、人源化等）、胆固醇、激素、抗病毒药物、肽、蛋白质、化学治疗药物、小分子、维生素、辅因子、核苷、核苷酸、寡核苷酸、酶性核酸、反义核酸、三链体寡核苷酸、2,5-A嵌合体、dsRNA、异构酶、aptamers、诱饵和其类似物，以及小的核酸分子，如短干扰核酸（siNA）、短干扰RNA（siRNA）、双链RNA（dsRNA）、微RNA（miRNA）、短发夹RNA（shRNA）和RNAi抑制分子，传递到相关的细胞和/或组织中，例如在个体或生物中。这种新型阳离子脂质、微粒、纳米粒子和转染剂在提供组合物以预防、抑制或治疗细胞、个体或生物的疾病、状况或特征方面是有用的。本文所描述的组合物通常称为配方分子组合物（FMC）或脂质纳米粒子（LNP）。
• Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
  申请人：Chen Tongqian

  公开号：US20080020058A1

  公开（公告）日：2008-01-24

  The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in a subject or organism. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules, such as antibodies (e.g., monoclonal, chimeric, humanized etc.), cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, dsRNA, allozymes, aptamers, decoys and analogs thereof, and small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), and RNAi inhibitor molecules, to relevant cells and/or tissues, such as in a subject or organism. Such novel cationic lipids, microparticles, nanoparticles and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism. The compositions described herein are generally referred to as formulated molecular compositions (FMC) or lipid nanoparticles (LNP).

  本发明涉及新型阳离子脂质、转染剂、微粒子、纳米粒子和短干扰核酸（siNA）分子。该发明还涉及组合物和使用方法，用于研究、诊断和治疗对基因表达和/或活性调节有反应的个体或生物的特征、疾病和状况。具体而言，该发明涉及新型阳离子脂质、微粒子、纳米粒子和转染剂，这些转染剂能够有效地转染或传递生物活性分子，如抗体（例如单克隆、嵌合、人源化等）、胆固醇、激素、抗病毒药物、肽、蛋白质、化疗药物、小分子、维生素、辅因子、核苷、核苷酸、寡核苷酸、酶性核酸、反义核酸、三链形成寡核苷酸、2,5-A嵌合体、dsRNA、异构酶、适配体、诱饵和其类似物以及小核酸分子，如短干扰核酸（siNA）、短干扰RNA（siRNA）、双链RNA（dsRNA）、微RNA（miRNA）、短发夹RNA（shRNA）和RNAi抑制分子，传递到相关的细胞和/或组织中，例如在个体或生物中。这些新型阳离子脂质、微粒子、纳米粒子和转染剂在提供组合物以预防、抑制或治疗细胞、个体或生物的疾病、状况或特征方面是有用的。所述组合物通常被称为配制分子组合物（FMC）或脂质纳米粒子（LNP）。
• LIPID NANOPARTICLE BASED COMPOSITIONS AND METHODS FOR THE DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES
  申请人：Chen Tongqian

  公开号：US20100105933A1

  公开（公告）日：2010-04-29

  The present invention relates to novel cationic lipids, transfection agents, microparticles, nanoparticles, and short interfering nucleic acid (siNA) molecules. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in a subject or organism. Specifically, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules, such as antibodies (e.g., monoclonal, chimeric, humanized etc.), cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, dsRNA, allozymes, aptamers, decoys and analogs thereof, and small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), and RNAi inhibitor molecules, to relevant cells and/or tissues, such as in a subject or organism. Such novel cationic lipids, microparticles, nanoparticles and transfection agents are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism. The compositions described herein are generally referred to as formulated molecular compositions (FMC) or lipid nanoparticles (LNP).

  本发明涉及新型阳离子脂质体、转染剂、微粒、纳米粒子和短干扰核酸（siNA）分子。本发明还涉及用于研究、诊断和治疗对基因表达和/或活性调节有响应的特征、疾病和情况的组合物和使用方法。具体而言，本发明涉及新型阳离子脂质体、微粒、纳米粒子和转染剂，可以有效地转染或传递生物活性分子，例如抗体（例如单克隆、嵌合、人源化等）、胆固醇、激素、抗病毒药物、肽、蛋白质、化疗药物、小分子、维生素、辅因子、核苷、核苷酸、寡核苷酸、酶性核酸、反义核酸、三股形成寡核苷酸、2,5-A嵌合体、dsRNA、等位酶、适配体、诱饵和其类似物以及小核酸分子，例如短干扰核酸（siNA）、短干扰RNA（siRNA）、双链RNA（dsRNA）、微RNA（miRNA）、短发夹RNA（shRNA）和RNAi抑制剂分子，传递到相关的细胞和/或组织中，例如在一个主体或生物体内。这种新型阳离子脂质体、微粒、纳米粒子和转染剂在提供组合物以预防、抑制或治疗细胞、主体或生物体中的疾病、情况或特征方面非常有用。本文所述的组合物通常称为配制分子组合物（FMC）或脂质纳米粒子（LNP）。